https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-04 / Vaccine 2009 Dec;28(2):542-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-04 / Vaccine 2009 Dec;28(2):542-72009-11-04 00:00:002019-02-15 08:44:10Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-01 / Scand. J. Immunol. 2009 Nov;70(5):481-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-01 / Scand. J. Immunol. 2009 Nov;70(5):481-92009-11-01 00:00:002019-02-15 09:16:49Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-01 / Radiother Oncol 2009 Nov;93(2):358-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-01 / Radiother Oncol 2009 Nov;93(2):358-632009-11-01 00:00:002019-02-15 09:17:31Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-01 / Expert Rev Anticancer Ther 2009 Nov;9(11):1577-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-01 / Expert Rev Anticancer Ther 2009 Nov;9(11):1577-822009-11-01 00:00:002019-02-15 08:48:32Heat-shock protein vaccines as active immunotherapy against human gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-01 / Gan To Kagaku Ryoho 2009 Nov;36(12):1988-90
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-01 / Gan To Kagaku Ryoho 2009 Nov;36(12):1988-902009-11-01 00:00:002009-11-01 00:00:00[The case of tumor escape mechanism by changing their tumor-associated antigens]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-11-01 / Gan To Kagaku Ryoho 2009 Nov;36(12):1964-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-11-01 / Gan To Kagaku Ryoho 2009 Nov;36(12):1964-62009-11-01 00:00:002009-11-01 00:00:00[Dendritic cell vaccine for intrahepatic cholangio cellular carcinoma–a study of relationship between immuno-reaction and clinical outcome]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-732009-10-27 00:00:002021-11-15 14:45:35Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-14 / Biol. Blood Marrow Transplant. 2010 Mar;16(3):320-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-14 / Biol. Blood Marrow Transplant. 2010 Mar;16(3):320-322009-10-14 00:00:002019-02-15 08:50:56Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-302009-10-13 00:00:002009-10-13 00:00:00Oncolytic virus therapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-06 / Mol. Ther. 2010 Feb;18(2):275-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-06 / Mol. Ther. 2010 Feb;18(2):275-842009-10-06 00:00:002009-10-06 00:00:00Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma
